EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2014	544/279.ccls. 514/234.2.ccls. 514/252.16.ccls. 514/264.1.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/05/16 10:44
L2	1420	514/234.2.ccls. 514/252.16.ccls. 514/264.1.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/05/16 12:24
L3	594	l1 not l2	US-PGPUB; USPAT; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/05/16 12:24

BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2488567	A1	20031218	CA 2003-2488567	200306 06
AU 2003238915	A1	20031222	AU 2003-238915	200306 06
EP 1515727	A2	20050323	EP 2003-734435	200306 06
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005176723	A1	20050811	US 2003-517754	200306 06
JP 2005534649	T	20051117	JP 2004-510711	200306 06
PRIORITY APPLN. INFO.:			US 2002-388066P P	200206 11
			WO 2003-US17821 W	200306 06

OTHER SOURCE(S): MARPAT 140:23240
ED Entered STN: 21 Dec 2003
AB Heterobicyclic compds. are claimed which are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.

L16 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:841822 HCAPLUS Full-text
DOCUMENT NUMBER: 140:87056
TITLE: SAR of 3,4-Dihydropyrido[3,2-d]pyrimidone p38 inhibitors
AUTHOR(S): Liu, Luping; **Stelmach, John E.**; **Natarajan, Swaminathan R.**; Chen, Meng-Hsin; Singh, Suresh B.; Schwartz, Cheryl D.; Fitzgerald, Catherine E.; O'Keefe, Stephen J.; Zaller, Dennis M.; Schmatz, Dennis M.; **Doherty, James B.**
CORPORATE SOURCE: Departments of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ, 07065, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(22), 3979-3982
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:87056
ED Entered STN: 28 Oct 2003
AB Development for a class of potent 3,4-dihydropyrido(3,2-d)pyrimidone inhibitors of p38a MAP kinase is described. Modification of N-1 aryl and C-6 arylsulfide in 3,4-dihydropyrido(3,2-d)pyrimidone analogs for the interaction with the hydrophobic pockets in p38 active site is also discussed.
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE